CRA was retained by counsel representing a leading global handset and smartphone manufacturer in an international arbitration related to valuation issues of balancing payments in a renegotiation of a broad patent cross-license with another leading global competitor. CRA provided analysis and rebuttal testimony to the tribunal regarding the non-SEP value contentions of the opposing party’s expert, including quantification of ten significant valuation errors resulting in overstatement of portfolio valuations. In addition, CRA identified material flaws in a patent portfolio citation analysis relied on by another opposing expert that counsel used during cross-examination to impeach the opposing expert’s methodology.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...